BUZZ-Hims & Hers slips on report of Medicare, Medicaid coverage for weight-loss drugs** Shares of telehealth firm Hims & Hers Health HIMS.N fall 6.5% to $61.88 premarket
** Trump administration is planning to cover weight-loss drugs under Medicare and Medicaid, Washington Post reports
** Proposed plan would permit state Medicaid programs and Medicare Part D insurance plans to voluntarily cover GLP-1 drugs such as Novo Nordisk's NOVOb.CO Ozempic and Wegovy, as well as Lilly's Mounjaro and Zepbound for weight management, report says
** Proposed plan is expected to start in April 2026 for Medicaid and in January 2027 for Medicare plans, Washington Post reports, citing documents
** As of last close, stock up 173% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.